Patents by Inventor Xiaochen PAN

Xiaochen PAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10786507
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Hao Chen, Xiaochen Pan
  • Publication number: 20190287571
    Abstract: Embodiments of the present application provide a method and device for playing a video. The method is applicable in a video monitoring system and includes: obtaining a video playing request carrying target time identification information; transferring and storing video index information buffered in a buffer area of the video monitoring system to a target storage area of the video monitoring system so as to update an index information packet stored in the target storage area; and playing a video file corresponding to the target time identification information based on the updated index information packet. It can be seen, in the embodiment, the video monitoring system allows playing the corresponding video file according to the user's video playing request, so as to meet the user's needs and thus provide a better user experience.
    Type: Application
    Filed: June 30, 2017
    Publication date: September 19, 2019
    Applicant: Hangzhou Hikvision Digital Technology Co., Ltd.
    Inventors: Lanxin WEI, Kui LI, Yadong PAN, Lujie SI, Xiaochen FENG
  • Publication number: 20190070181
    Abstract: The present invention relates to a formulation of ticagrelor or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to an improved formulation of ticagrelor or a pharmaceutically acceptable salt thereof, which is administered once a day. In the present invention, the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL within 2 hours; and the plasma concentration of ticagrelor in a subject is greater than about 0.2 ?g/mL at 12 hours after administration; and the maximum plasma concentration (Cmax) of ticagrelor or a pharmaceutically acceptable salt thereof in a subject is between about 0.2 ?g/mL and about 0.8 ?g/mL. The formulation of the present invention can reduce the frequency of administration, thereby improving patient compliance and reducing the risk of myocardial infarction or stroke induced by acute thrombosis which is caused by missed administration of ticagrelor.
    Type: Application
    Filed: September 6, 2018
    Publication date: March 7, 2019
    Inventors: Hao CHEN, Xiaochen PAN, Yun LU
  • Publication number: 20190030033
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR,5s, 6aS)—N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Application
    Filed: February 17, 2017
    Publication date: January 31, 2019
    Inventors: Yun LU, Hao CHEN, Xiaochen PAN